



Patient: **TEST, PATIENT** Age: 45 (02/23/72) Pathology #: **SPC-17-21124**  
 Acct#: Doctor: dpmg test Sex: FEMALE Date Obtained: 06/08/2017  
 3301 C Street #200E Date Received: 06/09/2017  
 SACRAMENTO, CA 95816

**SPECIMEN:** Cervical  
**CLINICAL DATA:**

**Cytologic and Molecular Results:**

**PAP DIAGNOSIS: ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE (ASC-US)**

**MOLECULAR RESULTS:**

HIGH RISK HPV RESULT: \*\*\* DETECTED \*\*\*  
 NEISSERIA GONORRHOEAE RESULTS: \*\*\*DETECTED\*\*\*  
 CHLAMYDIA TRACHOMATIS RESULTS: not detected  
 TRICHOMONAS VAGINALIS: not detected  
 \*CANDIDA ALBICANS RESULT: \*\*\*DETECTED\*\*\*  
 \*CANDIDA GLABRATA RESULT: \*\*\*DETECTED\*\*\*  
 \*GARDNERELLA VAGINALIS RESULT: \*\*\*DETECTED\*\*\*

**Additional Cytologic Findings**

**SPECIMEN ADEQUACY:** Satisfactory for evaluation  
**RECOMMENDATIONS:** Repeat smear as clinically indicated

**Prior PAP Smear Diagnoses: (3 most recent)**

<u>DATE</u>	<u>PATHOLOGY#</u>	<u>PAP DIAGNOSIS</u>	<u>MOLECULAR DIAGNOSES</u>
09/09/16	SPC-16-21113	HGSIL	High Risk HPV Positive
06/10/15	SPC-15-21096	WNL	High Risk HPV Negative, GC Negative, Chlamydia Negative
06/08/14	SPC-14-21095	WNL	High Risk HPV Negative

This summary of up to the most recent 3 Pap test results DOES NOT include comments about organisms seen on the Pap test, endometrial cells in the post-menopausal setting, or any other tissue studies performed. The provider must refer to the complete Pap test report or the clinical laboratory report for these items. This summary ONLY includes results of Pap tests or molecular tests performed by DPMG and does not include results from other institutions or laboratories.

The PAP smear is a screening test for cervical cancer with an inherent and irreducible false negative rate, the consequences of which may be minimized by obtaining regular annual PAP smears.

\*The LDT CV assay detects the presence of Candida Species RNA (C. albicans, C. tropicalis, C. dubliniensis and C. parapsilosis) by Real-Time Transcription Mediated Amplification.

\*The LDT CV Assay detects the presence of Candida glabrata RNA by Real-Time Transcription Mediated Amplification.

\*The LDT BV Assay detects the presence of Gardnerella vaginalis and Lactobacillus Spp. (L. jensenii, L. crispatus and L. gasseri) RNA by Real-Time Transcription Mediated Amplification. For cases in which the Gardnerella vaginalis result is indeterminate, the presence or absence of Lactobacillus RNA is used as a secondary criteria for interpretation.

Note: Results depend on sufficient levels of RNA to be detected, absence of inhibitors and adequate specimen collection. Results of any assay should be interpreted in conjunction with the clinical findings and should not preclude additional studies if results do not correlate. This ASR assay was developed and its analytical performance characteristics have been determined by Diagnostic Pathology Medical Group, Inc.

Molecular testing was performed with either the FDA-approved APTIMA HPV Assay kit, APTIMA HPV 16 18/45 Genotype Assay kit, APTIMA Combo 2 (CT/GC) Assay kit or APTIMA Trichomonas vaginalis Assay kit with one of the following modifications: a.) testing was performed on specimen types not specified on the kit insert. b.) the test procedure has been modified from the published kit insert procedure. This test was developed and its performance characteristics determined by Diagnostic Pathology Medical Group Inc. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

Interpretation on 06/10/2017 by **Alla Polyakova CT(ASCP)**  
 Electronically signed at Diagnostic Pathology Medical Group,  
 3301 C Street, Suite 200E SACRAMENTO, CA 95816

Interpretation on 06/10/2017 by **Kai Ni, M.D.**  
 Electronically signed at Diagnostic Pathology Medical Group,  
 3301 C Street, Suite 200E SACRAMENTO, CA 95816

Board Certified Cytopathologists